Vaccines for Papillomavirus (HPV) Infection

Abstract

Prophylactic HPV vaccination of both quadrivalent and bivalent vaccines has already been approved in Spain and is gaining popularity among Spanish women. Other European countries show similar trends.

With the use of vaccines against HPV, especially the tetravalent vaccine, in the short or medium-term there will be a lower rate of abnormal cytological results in vaccinated women, which is based on the expected preventive potential, which may range between 50 to 70% of the cases. Furthermore, with the use of the vaccine, in combination with present screening programs, we expect to reach a 92% reduction in the annual number of cases of cervical cancer and other associated pathologies in our country.